Hassing, Christina M. S. http://orcid.org/0000-0002-7170-8247
Mejdahl, Mathias Kvist
Lænkholm, Anne-Vibeke
Kroman, Niels
Knoop, Ann Søegaard
Tvedskov, Tove Holst Filtenborg
Funding for this research was provided by:
Kræftens Bekæmpelse (R246-A14574-19-S73)
Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat (20006-1846)
Dansk Kræftforsknings Fond
Region Sjællands Sundhedsvidenskabelige Forskningsfond (R19A283B198)
Dansk Brystkirurgisk Selskabs legat
Helsefonden (20-B-0003)
Interne Forskningsmidler, Herlev and Gentofte Hospital, Copenhagen University Hospital
Article History
Received: 4 July 2022
Accepted: 19 August 2022
First Online: 8 September 2022
Declarations
:
: Ann Søegaard Knoop reports personal fees from Novartis, Roche, Merck, Daiichi Sankyo, Gilead Sciences, Pfizer, Eli Lilly. Furthermore, she has been national or site investigator for Daiichi Sankyo and Sanofi. Tove Tvedskov reports speaker honorariums from Roche, MSD and Pfizer. Anne-Vibeke Lænkholm reports institutional research grants from Novartis and Astra Zeneca (AZ). Anne-Vibeke Lænkholm reports personal fees for participation in advisory boards, Novartis and AZ and for a research collaboration with Veracyte. No other potential conflicts of interest were reported.
: This study was approved by the Regional Research Ethics Committee of the Capital Region of Denmark (H-18045702) and by the Regional Data Protection Agency (P-2019-124).
: Exception for obtaining informed consent was given by the Regional Research Ethics Committee of the Capital Region of Denmark as the present study implied no health-related risks or discomfort for the involved patients.